Cost-effectiveness of respiratory syncytial virus prevention strategies in Mozambique: a modelling study.

ABSTRACT:

Background

Respiratory syncytial virus (RSV) is a leading cause of severe acute lower respiratory infections in children. The World Health Organization recently recommended two passive RSV immunisation strategies for global use, but prices are yet to be determined in low- and middle-income countries (LMICs).

Methods

We used a static cohort model to generate preliminary estimates of the potential health impact and cost-effectiveness of a maternal vaccine (RSVPreF, Abrysvo^®, Pfizer) and a long-acting infant mAb (Nirsevimab, Beyfortus^®, AstraZeneca, and Sanofi) over a 10-year period (2025-2034) in Mozambique. We incorporated cost-of-illness data from a recent study conducted in Maputo, Mozambique, and efficacy data from recent clinical trials. We compared

SUBMITTER: Guimaraes EL 

PROVIDER: S-EPMC12499514 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature